CXCR3 and melanoma: Systemic (Supplemental Fig. 1A) or tumor-restricted (Supplemental Fig. 1B) inhibition of CXCR3 signaling with the pharmacologic antagonist AMG487 reduced melanoma engraftment in the lung, in keeping with prior reports16, 20, demonstrating congruency with our model; interestingly, systemic AMG487 treatment enhanced melanoma engraftment of liver (Supplemental Fig. 1C), suggesting the role of CXCR3 in metastatic engraftment is confined to specific organs, including the lungs.